



Luxembourg, 4 April 2024

Scientific Committee on Consumer Safety (SCCS)

7th Plenary meeting 2022-2026

27 March 2024, Luxembourg (hybrid)

Minutes

1. WELCOME AND APOLOGIES (CHAIR: PROF. Q. CHAUDHRY)

The Chair welcomed all participants, including the SCHEER representative and DG GROW. The agenda was adopted. No apology was received.

The minutes of the previous plenary meeting were adopted by the SCCS via written process and published on the website: [SCCS - Plenary sessions 2022 - 2026 \(europa.eu\)](https://europa.eu/sccs/plenary-sessions-2022-2026)

The Chair invited participants to declare any interest regarding matters on the agenda. None of the participants declared any interest conflicting with the matters on the agenda.

2. LIST OF POINTS DISCUSSED

2.1 NEW REQUESTS/MANDATES/ GENERAL INFORMATION FROM DG GROW

The following new mandates were discussed and adopted:

1. Salicylic acid - children's exposure
2. Butylparaben - children's exposure
3. Prostaglandin and analogues: 'Ethyl Tafluprostamide' (DDDE) (CAS No. 1185851-52-8, EC No. 867-521-0), Methylamido-Dihydro-Noralfaprostal (MDN) (CAS No. 155206-01-2, EC No.-) and Isopropyl Cloprostenate (IPCP) (CAS No. 157283-66-4, EC No.-) used in cosmetics products
4. Submission II for HC Red 18 (B124)
5. Submission II for HC Yellow 16 (B123)

Mandates will be published here: [SCCS - Mandates | Public Health \(europa.eu\)](https://europa.eu/sccs/mandates-public-health)
Commission will appoint the selected rapporteurs.

2.2. DRAFT OPINIONS

WG cosmetic ingredients

COMMENTS ON ADOPTED OPINIONS

The following final Opinions were adopted together with the SCCS responses to the comments received; the final texts will be published on [SCCS - Opinions \(europa.eu\)](https://europa.eu/sccs/opinions).

- Aluminium (updated use concentration)
- Benzophenone-4

DRAFT OPINIONS DISCUSSED

The following preliminary Opinions were adopted and will be published for comments on:
[SCCS - Opinions \(europa.eu\)](https://ec.europa.eu/sccs/opinions/)

- Triphenylphosphate
- Silver
- Citral

The following scientific advice will be further discussed during the next WG meeting, together with SCCS responses to comments received:

- TiO₂ genotoxicity via oral/inhalable products

WG nanomaterials

The following Opinions were discussed:

- 3 coatings for TiO₂: it will be further discussed in the next nano WG meeting
- Hydroxyapatite (HAP) submission IV: a request to Applicant has been prepared

3. INFORMATION FROM COMMISSION/ CHAIRS / MEMBERS

- Commission revision of the Cosmetic Regulation is ongoing.
- Commission Regulation (EU) 2024/858 of 14 March 2024 amending Regulation (EC) No 1223/2009 of the European Parliament and of the Council as regards the use of the nanomaterials Styrene/Acrylates copolymer, Sodium Styrene/Acrylates copolymer, Copper, Colloidal Copper, Hydroxyapatite, Gold, Colloidal Gold, Gold Thioethylamino Hyaluronic Acid, Acetyl heptapeptide-9 Colloidal gold, Platinum, Colloidal Platinum, Acetyl tetrapeptide-17 Colloidal Platinum and Colloidal Silver in cosmetics products was published in the *OJ L of 15/03/2024*
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L_202400858

4. ANY OTHER BUSINESS

Next plenary (hybrid) meetings:

- 20 June and 25 October 2024
